Compare Stocks: NCEL, TELO, ANVS, and CTOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.37 -19.4%	$1.79	$1.32 ▼ $5.50	$72.43M	1.24	525,033 shs	7.25 million shs
CTOR Citius Oncology	$0.79 +1.9%	$0.70	$0.49 ▼ $2.25	$72.31M	3.52	75,599 shs	13,949 shs
NCEL NLS Pharmaceutics	$3.35	$3.60	$1.83 ▼ $24.60	$19.35M	0.94	12,328 shs	9,009 shs
TELO Telomir Pharmaceuticals	$1.16 +3.6%	$1.17	$0.89 ▼ $2.09	$77.03M	-0.25	49,100 shs	64,229 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-19.65%	-24.10%	-26.93%	-27.32%	-40.12%
CTOR Citius Oncology	+1.86%	+0.24%	+20.03%	+1.56%	-59.79%
NCEL NLS Pharmaceutics	0.00%	-2.05%	-2.90%	+14.33%	-83.50%
TELO Telomir Pharmaceuticals	+3.57%	-2.52%	+0.87%	-4.13%	-1.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.37 -19.4%	$1.79	$1.32 ▼ $5.50	$72.43M	1.24	525,033 shs	7.25 million shs
CTOR Citius Oncology	$0.79 +1.9%	$0.70	$0.49 ▼ $2.25	$72.31M	3.52	75,599 shs	13,949 shs
NCEL NLS Pharmaceutics	$3.35	$3.60	$1.83 ▼ $24.60	$19.35M	0.94	12,328 shs	9,009 shs
TELO Telomir Pharmaceuticals	$1.16 +3.6%	$1.17	$0.89 ▼ $2.09	$77.03M	-0.25	49,100 shs	64,229 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-19.65%	-24.10%	-26.93%	-27.32%	-40.12%
CTOR Citius Oncology	+1.86%	+0.24%	+20.03%	+1.56%	-59.79%
NCEL NLS Pharmaceutics	0.00%	-2.05%	-2.90%	+14.33%	-83.50%
TELO Telomir Pharmaceuticals	+3.57%	-2.52%	+0.87%	-4.13%	-1.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.25	Hold	$12.00	775.91% Upside
CTOR Citius Oncology	2.33	Hold	$6.00	657.38% Upside
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	586.57% Upside
TELO Telomir Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest NCEL, TELO, ANVS, and CTOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	TELO Telomir Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.43 per share	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	N/A

Latest NCEL, TELO, ANVS, and CTOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	3.47	3.47
CTOR Citius Oncology	0.25	0.73	0.34
NCEL NLS Pharmaceutics	N/A	0.76	0.76
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CTOR Citius Oncology	70.52%
NCEL NLS Pharmaceutics	N/A
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CTOR Citius Oncology	9.82%
NCEL NLS Pharmaceutics	16.40%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	42.61 million	33.74 million	Optionable
CTOR Citius Oncology	N/A	92.98 million	83.85 million	N/A
NCEL NLS Pharmaceutics	6	5.78 million	4.83 million	Not Optionable
TELO Telomir Pharmaceuticals	1	68.78 million	57.52 million	N/A

NCEL, TELO, ANVS, and CTOR Headlines

Recent News About These Companies

Telomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on Wednesday

August 26, 2026 | americanbankingnews.com

Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday

August 26, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

August 13, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?

August 12, 2026 | marketbeat.com

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn

April 30, 2026 | tipranks.com

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

April 30, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

April 24, 2026 | usatoday.com

Telomir Pharmaceuticals Inc.

April 2, 2026 | barrons.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NCEL, TELO, ANVS, and CTOR Company Descriptions

Annovis Bio NYSE:ANVS

$1.37 -0.33 (-19.41%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$1.40 +0.03 (+2.19%)

As of 09:14 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Citius Oncology NASDAQ:CTOR

$0.79 +0.01 (+1.86%)

Closing price 09/3/2026 03:59 PM Eastern

Extended Trading

$0.77 -0.03 (-3.31%)

As of 09:15 AM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

NLS Pharmaceutics NASDAQ:NCEL

$3.35 0.00 (0.00%)

As of 09/3/2026 03:51 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Telomir Pharmaceuticals NASDAQ:TELO

$1.16 +0.04 (+3.57%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.14 -0.01 (-1.29%)

As of 09:15 AM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCEL, TELO, ANVS, and CTOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCEL, TELO, ANVS, and CTOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCEL, TELO, ANVS, and CTOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NCEL, TELO, ANVS, and CTOR Company Descriptions

Annovis Bio NYSE:ANVS

Citius Oncology NASDAQ:CTOR

NLS Pharmaceutics NASDAQ:NCEL

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCEL, TELO, ANVS, and CTOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCEL, TELO, ANVS, and CTOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCEL, TELO, ANVS, and CTOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NCEL, TELO, ANVS, and CTOR Company Descriptions

Annovis Bio NYSE:ANVS

Citius Oncology NASDAQ:CTOR

NLS Pharmaceutics NASDAQ:NCEL

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools